MX2009013515A - Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica. - Google Patents

Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.

Info

Publication number
MX2009013515A
MX2009013515A MX2009013515A MX2009013515A MX2009013515A MX 2009013515 A MX2009013515 A MX 2009013515A MX 2009013515 A MX2009013515 A MX 2009013515A MX 2009013515 A MX2009013515 A MX 2009013515A MX 2009013515 A MX2009013515 A MX 2009013515A
Authority
MX
Mexico
Prior art keywords
naphthyridones
therapeutics
alkynyl
derivatives
preparation
Prior art date
Application number
MX2009013515A
Other languages
English (en)
Inventor
Francoise Bono
Antoine Alam
Olivier Duclos
Gary Mccort
Sandrine Biscarrat
Isabelle Blanc
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2009013515A publication Critical patent/MX2009013515A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

La invención se refiere a derivados de 7-alquinil-1,8-naftiridonas que tienen la fórmula general (I): en la cual R1, R2, R3 y R4 son tal como se definen en la descripción. La invención también se refiere al procedimiento para su preparación y al uso de los mimos en terapéutica.
MX2009013515A 2007-06-13 2008-06-11 Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica. MX2009013515A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0704192A FR2917412B1 (fr) 2007-06-13 2007-06-13 Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique
PCT/FR2008/000793 WO2009007535A2 (fr) 2007-06-13 2008-06-11 Derives de 7 -alkynyl-1.8-naphthyrid0nes, leur preparation et leur application en therapeutique

Publications (1)

Publication Number Publication Date
MX2009013515A true MX2009013515A (es) 2010-01-27

Family

ID=38870275

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009013515A MX2009013515A (es) 2007-06-13 2008-06-11 Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.

Country Status (44)

Country Link
US (1) US8470847B2 (es)
EP (1) EP2158201B1 (es)
JP (1) JP5343072B2 (es)
KR (1) KR101517636B1 (es)
CN (1) CN101679427B (es)
AP (1) AP2590A (es)
AR (1) AR066954A1 (es)
AT (1) ATE505469T1 (es)
AU (1) AU2008274099B2 (es)
CA (1) CA2690337C (es)
CL (1) CL2008001775A1 (es)
CO (1) CO6150150A2 (es)
CR (1) CR11157A (es)
CY (1) CY1111631T1 (es)
DE (1) DE602008006188D1 (es)
DK (1) DK2158201T3 (es)
DO (1) DOP2009000264A (es)
EA (1) EA016939B1 (es)
EC (1) ECSP099791A (es)
ES (1) ES2365073T3 (es)
FR (1) FR2917412B1 (es)
GT (1) GT200900309A (es)
HK (1) HK1141790A1 (es)
HN (1) HN2009003402A (es)
HR (1) HRP20110515T1 (es)
IL (1) IL202640A (es)
JO (1) JO2682B1 (es)
MA (1) MA31567B1 (es)
ME (1) ME00961B (es)
MX (1) MX2009013515A (es)
MY (1) MY157754A (es)
NI (1) NI200900211A (es)
NZ (1) NZ581839A (es)
PA (1) PA8781701A1 (es)
PE (1) PE20090307A1 (es)
PL (1) PL2158201T3 (es)
PT (1) PT2158201E (es)
SI (1) SI2158201T1 (es)
SV (1) SV2009003429A (es)
TN (1) TN2009000483A1 (es)
TW (1) TWI405762B (es)
UA (1) UA96994C2 (es)
UY (1) UY31152A1 (es)
WO (1) WO2009007535A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2917413B1 (fr) 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique
FR2933700B1 (fr) 2008-07-08 2010-07-30 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2952934B1 (fr) 2009-11-23 2012-06-22 Sanofi Aventis Derives de pyridino-pyridinones, leur preparation et leur application en therapeutique
FR2954943B1 (fr) * 2010-01-07 2013-03-01 Sanofi Aventis Derives de pyridino-pyridinones arylsulfonamides, leur preparation et leur application en therapeutique
FR2955109B1 (fr) * 2010-01-08 2012-09-07 Sanofi Aventis Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
FR2965263A1 (fr) 2010-09-24 2012-03-30 Sanofi Aventis Derives de thienopyridine nicotinamide, leur preparation et leur application en therapeutique
EP2524915A1 (en) 2011-05-20 2012-11-21 Sanofi 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors
JP5748210B2 (ja) * 2011-05-26 2015-07-15 日本化薬株式会社 複素環化合物の製造方法
JP6226981B2 (ja) * 2012-07-17 2017-11-08 サノフイ 肝細胞癌を処置するためのｖｅｇｆｒ−３阻害剤の使用
CN108558869B (zh) * 2018-05-10 2019-04-09 西安培华学院 用于治疗肝癌的化合物及其制剂
CN110981869A (zh) * 2019-12-10 2020-04-10 天津科技大学 一种1,8-双氮杂色酮的合成方法及其在抗糖尿病药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69631423T2 (de) * 1995-08-02 2004-12-02 Darwin Discovery Ltd., Slough Chinolone und deren therapeutische verwendung
EP0978516A4 (en) * 1998-01-29 2001-01-10 Suntory Ltd 1-CYCLOALKYL-1,8-NAPHTHYRIDINE-4-ONE DERIVATIVES HAVING PHOSPHODIESTERASE IV INHIBITING ACTIVITY
DE60205899T2 (de) * 2001-05-24 2006-06-29 Merck Frosst Canada & Co, Kirkland 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
JP2008501628A (ja) 2004-06-02 2008-01-24 武田薬品工業株式会社 インドール誘導体およびがんの治療用途
FR2917413B1 (fr) * 2007-06-13 2009-08-21 Sanofi Aventis Sa Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
IL202640A (en) 2014-01-30
ME00961B (me) 2012-06-20
JP2010529178A (ja) 2010-08-26
AP2590A (en) 2013-02-04
NI200900211A (es) 2010-07-15
CN101679427A (zh) 2010-03-24
WO2009007535A3 (fr) 2009-04-09
DE602008006188D1 (de) 2011-05-26
CA2690337C (fr) 2015-08-11
EA016939B1 (ru) 2012-08-30
JP5343072B2 (ja) 2013-11-13
AP2010005099A0 (en) 2010-02-28
TWI405762B (zh) 2013-08-21
GT200900309A (es) 2012-01-26
KR101517636B1 (ko) 2015-05-04
MA31567B1 (fr) 2010-08-02
DOP2009000264A (es) 2009-12-15
HK1141790A1 (es) 2010-11-19
MY157754A (en) 2016-07-15
CR11157A (es) 2010-03-23
UA96994C2 (ru) 2011-12-26
AR066954A1 (es) 2009-09-23
FR2917412B1 (fr) 2009-08-21
ATE505469T1 (de) 2011-04-15
WO2009007535A2 (fr) 2009-01-15
IL202640A0 (en) 2010-06-30
CN101679427B (zh) 2013-02-20
ES2365073T3 (es) 2011-09-21
UY31152A1 (es) 2009-01-30
HRP20110515T1 (hr) 2011-08-31
TW200911802A (en) 2009-03-16
JO2682B1 (en) 2013-03-03
CA2690337A1 (fr) 2009-01-15
KR20100020000A (ko) 2010-02-19
TN2009000483A1 (fr) 2011-03-31
HN2009003402A (es) 2012-02-27
AU2008274099B2 (en) 2013-05-16
FR2917412A1 (fr) 2008-12-19
EA201070009A1 (ru) 2010-06-30
CO6150150A2 (es) 2010-04-20
ECSP099791A (es) 2010-01-29
AU2008274099A1 (en) 2009-01-15
PE20090307A1 (es) 2009-04-20
US8470847B2 (en) 2013-06-25
CY1111631T1 (el) 2015-10-07
EP2158201A2 (fr) 2010-03-03
DK2158201T3 (da) 2011-08-01
US20100144757A1 (en) 2010-06-10
PT2158201E (pt) 2011-07-05
SI2158201T1 (sl) 2011-07-29
PL2158201T3 (pl) 2011-09-30
SV2009003429A (es) 2010-02-05
PA8781701A1 (es) 2009-01-23
BRPI0814035A2 (pt) 2020-08-04
CL2008001775A1 (es) 2009-09-25
NZ581839A (en) 2011-05-27
EP2158201B1 (fr) 2011-04-13

Similar Documents

Publication Publication Date Title
MX2009013515A (es) Derivados de 7-alquinil-1,8-naftiridonas, su preparacion y su aplicacion en terapeutica.
UA102858C2 (ru) Производные пиридино-пиридинонов, способ их получения и применения в терапии
GEP20125652B (en) cMET INHIBITORS
TW201713640A (en) Bruton's tyrosine kinase inhibitors
TN2011000279A1 (en) Novel pyrazole -4-n-alkoxycarboxamides as microbiocides
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
MX2009008798A (es) Derivados de iminipiridina y sus usos como microbicidas.
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
MY153921A (en) Aminopyrazole derivatives
MX353308B (es) Derivados fosforosos como inhibidores de cinasa.
MX2008013582A (es) Derivados de pirimidina como inhibidores de fosfatidilinositol-3-c inasa.
MX2009004435A (es) Tinturas dispersas, su preparacion y su uso.
WO2009077471A3 (de) Azolylmethyloxirane, ihre verwendung sowie sie enthaltende mittel
NZ579928A (en) Fluorinated derivatives of deferiprone
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
MX2012005225A (es) Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso.
MX342947B (es) Tratamiento de diabetes tipo 2.
MX2009010176A (es) Derivados de aza-adamantano 4-substituidos y metodos de uso de los mismos.
WO2009035959A3 (en) Radiofluorination methods
MX2012010127A (es) Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos.

Legal Events

Date Code Title Description
FG Grant or registration